noscript

QBiotics Group

Australia|Pharmaceuticals

QBiotics Investor Overview : Game-Changing Pharmaceuticals

Cancer is responsible for one in six deaths, making it the second most common cause of death globally.  

Surgery, radiotherapy, chemotherapy and immunotherapies for cancer have varying degrees of success, side effects and recovery; and they are often very expensive. 

There is a compelling need for a non-invasive treatment which targets and kills only the tumour, and ideally any secondary tumours, with minimal/no systemic side effects; at a lower cost.

QBiotics’ outstanding advantages :

The game-changing anti-cancer compound, tigilanol tiglate, injected directly into solid tumours is disrupting the treatment of various cancers. Its unique mode of action completely destroys the tumour and promotes rapid and complete healing of the site, often after one injection. It has been launched for Veterinary use in the USA, Europe (27 countries) and Australia). Numerous clinical trials are in progress for various cancers in humans.

A unique wound healing agent, EBC-1013, has a novel mode of action combining antimicrobial activity, biofilm disruption and immune system stimulation for both human and veterinary use. Chronic wounds impact tens of millions of people globally and cost billions of dollars pa.

The simultaneous human/veterinary development model delivers earlier, greater returns. 

Proprietary drug discovery technology EcoLogic™ identifies next-generation antibiotics and anti-inflammatories, expanding the product portfolio and providing future growth opportunities. 

World-class Board and Leadership Team to take the company public and to becoming one of Australia’s foremost healthcare successes. They have a proven track record of growing and listing global companies which have very significant market capitalisations.

Predicted to be 'one of the country’s healthcare success stories; in the same vein as CSL, Cochlear and ResMed.' 

$85m raised in 2021 provides a 3-year runway to achieve key milestones.  

Clear exit strategy through an IPO and listing on the stock exchange.  

The only way to acquire QBiotics shares is through private, off-market share sales. 

Parcels of shares are available for purchase through Achieve Capital Pty Limited. Min. purchase is $5,000 worth of shares. Contact [email protected]

Background & History

Cras eleifend purus vitae mattis imperdiet.



Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.



Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.



Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.



Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma


Open an account to get
access to more details

Key Achievement & Milestones

Cras eleifend purus vitae mattis imperdiet.



Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.



Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.



Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.



Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma


Open an account to get
access to more details

Board & Management

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.



Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.



Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.

Proin mollis, magna consequat placerat tempus, lectus dui porttitor augue, eget vulputate orci augue nec nisl. Integer sagit


Open an account to get
access to more details

Investment Highlights

Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.

Duis vitae mi neque.



Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.



Proin neque lacus, semper vel ex at, eleifend rhoncus est.

Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.



Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu. Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mollis, eget aliquet odio tincidunt.

Phasellus faucibus sem mauris, sed iaculis nisl egestas sed. Sed sit amet gravida elit, sagittis sollicitudin nulla. Vivamus auctor arcu eu scelerisque convallis. Phasellus scelerisque ultrices tincidunt. Curabitur odio libero, faucibus et felis nec, pulvinar facilisis urna. Interdum et malesuada fames ac ante ipsum primis in faucibus. Maecenas ultrices in velit at ultrices.



Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet. Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim.

In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum vel


Open an account to get
access to more details

See more exiting opportunities on CapitalHQ

BetterX

BetterX offers B2B and B2B2C white-label and API driven software solutions to traditional institutions to offer digital asset services to their clients.

flag_australia
Australia AUD
Fintech Seed Round

Paycepaid

Paycepaid is a Software as a Service debt collection solution unlike any on the market today with a heavy focus on the debtor. Empowering businesses to manage their end to end collections while providing debtors with a magnitude of options to reduce financial stress and anxiety.

flag_australia
Australia AUD
Online Marketplace Seed Round

Wholesale Investor

Wholesale Investor, with over 45,000 subscribers, is a leading private capital marketplace operating across Australia, Singapore, and the UK. It has a 15-year track record of connecting private market opportunities with HNW, professional, and family office investors. In just 4 years, our product...

flag_australia
Australia AUD
Fintech Series B+ Software-as-a-Service

PRIMAL ORGANIX

Primal Organix has created the world’s first botanically derived Terpene blended anti-anxiety health supplement that manages anxiety in minutes. Our purpose is to support positive mental ill-health and well-being in all human beings.

flag_australia
Australia AUD
Healthcare Series A

Sustainable Fintech Fund

Startupbootcamp, the #1 Accelerator in the world outside of the US, established in 2010, operates in 27 countries around the globe, has accelerated over 1600+ startups with a success rate of 76% remaining active, raised over $2.2B in total funding, a network of more than 300+ investors, 5000...

flag_australia
Australia AUD
Fintech Fund

Misio

Sustainability performance and stakeholder communications are now fundamental to overall corporate profitability and impact. Misio simplifies a complex eco-system to help large & listed companies shift the sustainability narrative out from annual reports into easy to understand digital...

flag_australia
Australia AUD
Sustainability Bridging Round

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

National Property Group

National Property Group (NPG) is a trusted alternative provider of property data and insights empowering informed decisions for all property market participants. NPG relaunched its property data & analytics intelligence platform in 2021, delivering instant insights from more than 40 years of...

flag_australia
Australia AUD
Proptech Series B+

Novapep

Novapep, an Australian/US biotech, has developed a patented peptide structure called biparediteTM as an oral inflammatory bowel disease therapy, which will be a cost effective first-in-class drug. Biparetide has been shown in animals to be as effective as expensive, injectable biologic drugs (a...

flag_australia
Australia AUD
Biotechnology Seed Round

Join over 45,000+ sophisticated investors

Join Now